BlossomHill Therapeutics (BLSM) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($543.7 million vs $530.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | PBYI |
|---|---|---|
| Share price | $17.11 | $10.28 |
| Market cap | $543.68M | $530.65M |
| 1-day change | +1.33% | +3.11% |
| YTD return | — | +67.56% |
| 1-year return | — | +90.63% |
| 5-year return | — | +64.79% |
| P/E ratio (TTM) | — | 20.16 |
| Forward P/E | — | 29.37 |
| EPS (TTM) | $-4.70 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $10.31 |
| 52-week low | $15.25 | $4.58 |
| Distance from 52-week high | -38.89% | -0.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +106.96% | — |
| Average volume | 261.23K | 320.69K |
| Shares outstanding | 31.78M | 51.62M |
| Employees | 69 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
BLSM vs PBYI FAQ
Which is bigger, BlossomHill Therapeutics or Puma Biotechnology?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $543.68M compared with $530.65M for Puma Biotechnology (PBYI).
Are BlossomHill Therapeutics and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.